

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

February 2024

The logo for PHARMAC, featuring the word "PHARMAC" in a large, bold, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, all-caps, sans-serif font below it. The logo is centered within a white circle that overlaps a background of stylized, concentric, wavy lines in shades of gray and white.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 February 2024	3
Section H changes to Part II	7
Index	16

Summary of decisions

EFFECTIVE 1 FEBRUARY 2024

- Acitretin (Novatrelin) cap 10 mg and 25 mg – price increase and addition of PSS
- Alendronate sodium (Fosamax) tab 70 mg – price increase and addition of PSS
- Alendronate sodium with colecalciferol (Fosamax Plus) tab 70 mg with colecalciferol 5,600 iu – price increase and addition of PSS
- Amino acid formula (Elecare (Unflavoured) and Elecare (Vanilla) powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can, 400 g – price increase
- Amino acid formula (Elecare LCP) powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can, 400 g – price increase
- Amino acid formula (without isoleucine, methionine, threonine and valine) (e.g. MMA/PA Anamix Infant, XMTVI Maxamaid and XMTVI Maxamum) – moved chemical to new Therapeutic Group heading
- Amino acid formula (without leucine) (e.g. IVA Anamix Infant, XLEU Maxamaid and XLEU Maxamum) – moved chemical to new Therapeutic Group heading
- Amino acid formula (without lysine) (GA Explore 5 and GA Express) – new listing
- Amino acid formula (without methionine) (HCU Explore 5 and HCU Express 15) – new listing
- Amino acid formula (without methionine, threonine and valine) (MMA/PA Explore 5 and MMA/PA Express 15) – new listing
- Amino acid formula (without phenylalanine and tyrosine) (TYR Explore 5) powder (neutral), 5 g protein, 5.3 g carbohydrate, 0.2 g fat per 12.5 g sachet – new listing
- Amino acid formula (without phenylalanine) (PKU Restore Powder, PKU Start, PKU Explore 5, PKU Explore 10 and PKU Express 20) – new listing
- Amino acid formula (without valine, leucine and isoleucine) (MSUD Explore 5 and MSUD Express 15) – new listing
- Arginine (Arginine2000) powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet – new listing
- Betamethasone dipropionate (Diprosone) crm 0.05% and oint 0.05% – addition of PSS
- Citric acid with magnesium carbonate hydrate and sodium picosulfate (e.g. PicoPrep Orange) powder for oral soln 12 g with magnesium carbonate hydrate 7.4 g and sodium picosulfate 10 mg per sachet – amended chemical name, presentation description and brand name
- Citrulline (Citrulline1000) powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet – new listing
- Clarithromycin (Klacid IV) inj 500 mg vial – new listing and addition of PSS

Summary of decisions – effective 1 February 2024 (continued)

- Dabigatran (Pradaxa) cap 75 mg, 110 mg and 150 mg – price decrease and addition of PSS
- Enteral feed 1 kcal/ml liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle (Osmolite RTH) and liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle (Jevity RTH) – price increase
- Enteral feed 1.2 kcal/ml (Jevity Plus RTH) liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag – new listing
- Enteral feed 1.5 kcal/ml liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can (Ensure Plus HN), liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag (Ensure Plus HN RTH) and liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag (Jevity HiCal RTH) – price increase
- Enteral feed 2 kcal/ml (Ensure Two Cal HN RTH) liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle – price increase
- Flucloxacilin (Flucloxin) inj 250 mg vial and 500 mg vial – price increase and addition of PSS
- Glycomacropeptide and amino acid contains some phenylalanine (Camino Pro Bettermilk, PKU Glytactin RTD 15, PKU Glytactin RTD 15 Lite and PKU Build 10) – new listing
- Glycomacropeptide and amino acid contains some phenylalanine (PKU Build 20 Chocolate, PKU Build 20 Raspberry Lemonade, PKU Build 20 Smooth, PKU Build 20 Vanilla, PKU sphere20 Lemon, PKU sphere20 Chocolate, PKU sphere20 Red Berry, PKU sphere20 Vanilla, PKU sphere20 Banana) – moved chemical to new Therapeutic Group and revoke delisting
- Glycomacropeptide and amino acid contains some tyrosine and phenylalanine (TYR Sphere 20) powder (Red Berry), 20 g protein, 6.3 carbohydrate, 1.6 g fat per 35 g sachet and Powder (Vanilla), 20 g protein, 6.0 g carbohydrate, 1.6 g fat per 35 g sachet – new listing
- High amylopectin corn-starch (Glycosade) powder 0 g protein, 53 g carbohydrate, 0 g fat per 60 g sachet – new listing
- Influenza vaccine inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine) (Influvac Tetra (2024 formulation)) – new listing and amended restriction criteria
- Isoleucine (Isoleucine50) powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet – new listing
- Leucine (Leucine100) powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet – new listing
- Low electrolyte enteral feed 1.8 kcal/ml (Nepro HP RTH) liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle – to be delisted 1 August 2024

Summary of decisions – effective 1 February 2024 (continued)

- Low electrolyte oral feed 1.8 kcal/ml (Nepro HP (Strawberry) and Nepro HP (Vanilla)) liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton – price increase
 - Low-GI enteral feed 1 kcal/ml (Glucerna Select) liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml bottle – price increase
 - Macrogol 3350 with ascorbic acid, potassium chloride, sodium chloride and citric acid with magnesium carbonate hydrate and sodium picosulfate (e.g. *Prepkit Orange*) Powder for oral soln 52.9 g with ascorbic acid 6 g, potassium chloride 740 mg, sodium chloride 2.6 g and sodium sulphate 5.6 g per sachet (1) and powder for oral soln citric acid 12 g with magnesium carbonate hydrate 7.4 g and sodium picosulfate 10 mg per sachet (2) – amended chemical name, presentation description and brand name
 - Metabolic products – amended restriction criteria
 - Methenamine (hexamine) hippurate (Hiprex) tab 1 g – new Pharmacode listing
 - Methenamine (hexamine) hippurate (Hiprex) tab 1 g – to be delisted from 1 July 2024
 - Morphine sulphate (Wockhardt) oral liq 2 mg per ml, 100 ml – price increase
 - Nilotinib (Tasigna) cap 150 mg and 200 mg – amended restriction criteria
 - Paediatric enteral feed 1 kcal/ml (Pediasure RTH) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag – price increase
 - Paediatric oral feed 1 kcal/ml (Pediasure (Chocolate), Pediasure (Strawberry) and Pediasure (Vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bottle – price increase
 - Paediatric oral feed 1 kcal/ml (Pediasure (Vanilla)) liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, can – price increase
 - Paediatric oral feed 1.5 kcal/ml (Pediasure Plus) liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle – new listing
 - Peptide-based enteral feed 1.5 kcal/ml (Vital) liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle – price increase
 - Phenylalanine (Phenylalanine50) powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet – new listing
 - Polyethylene glycol 400 and propylene glycol eye drops 0.4% with propylene glycol 0.3%, 10 ml bottle – new listing
 - Supplements for Glutaric Aciduria Type 1 – amended Therapeutic Group heading
 - Supplements for Homocystinuria – amended Therapeutic Group heading
 - Supplements for MSUD and Short chain enoyl coA hydratase deficiency – amended Therapeutic Group heading
 - Supplements for Phenylketonuria – amended Therapeutic Group heading
-

Summary of decisions – effective 1 February 2024 (continued)

- Supplements for Tyrosinaemia – amended Therapeutic Group heading
- Supplements for Urea Cycle Disorders – amended Therapeutic Group heading
- Tyrosine (Tyrosine1000) powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet – new listing
- Valine (Valine50) powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet – new listing

Price (ex man. Excl. GST) \$	Brand or Generic Manufacturer
------------------------------------	-------------------------------------

Section H changes to Part II

Effective 1 February 2024

ALIMENTARY TRACT AND METABOLISM

- | | | |
|----|--|------------------------------|
| 14 | CITRIC ACID WITH MAGNESIUM CARBONATE HYDRATE OXIDE AND SODIUM PICOSULFATE
(amended chemical name, presentation description and brand name)
Powder for oral soln 12 g with magnesium oxide 3.5 g
magnesium carbonate hydrate 7.4 g and sodium
picosulfate 10 mg per sachet | <i>e.g. PicoPrep Orange</i> |
| 14 | MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE, SODIUM CHLORIDE AND CITRIC ACID
WITH MAGNESIUM CARBONATE HYDRATE OXIDE AND SODIUM PICOSULFATE (amended chemical name,
presentation description and brand name)
Powder for oral soln 52.9 g with ascorbic acid 6 g,
potassium chloride 740 mg, sodium chloride 2.6 g and
sodium sulphate 5.6 g per sachet (1) and powder for
oral soln citric acid 12 g with magnesium oxide 3.5 g
magnesium carbonate hydrate 7.4 g and
sodium picosulfate 10 mg per sachet (2) | <i>e.g. Preplit-Ø Orange</i> |

BLOOD AND BLOOD FORMING ORGANS

- | | | | |
|----|---|----|----------------|
| 35 | DABIGATRAN (↓ price and addition of PSS)
Cap 75 mg – 5% DV Jul-24 to 2026 27.99 | 60 | Pradaxa |
| | Cap 110 mg – 5% DV Jul-24 to 2026 27.99 | 60 | Pradaxa |
| | Cap 150 mg – 5% DV Jul-24 to 2026 27.99 | 60 | Pradaxa |

DERMATOLOGICALS

- | | | | |
|----|--|------|-------------------|
| 71 | BETAMETHASONE DIPROPIONATE (addition of PSS)
Crn 0.05% – 5% DV Jul-24 to 2026 36.00 | 50 g | Diprosone |
| | Note: DV limit applies to the pack sizes of greater than 30 g.
Oint 0.05% – 5% DV Jul-24 to 2026 36.00 | 50 g | Diprosone |
| | Note: DV limit applies to the pack sizes of greater than 30 g. | | |
| 72 | ACITRETIN (↑ price and addition of PSS)
Cap 10 mg – 5% DV Jul-24 to 2026 26.20 | 60 | Novatretin |
| | Cap 25 mg – 5% DV Jul-24 to 2026 57.37 | 60 | Novatretin |

INFECTIONS

- | | | | |
|----|--|----|------------------|
| 92 | CLARITHROMYCIN (new listing and addition of PSS)
→ Inj 500 mg vial – 5% DV Jul-24 to 2026 9.10 | 1 | Klacid IV |
| | Note – Martindale inj 500 mg vial to be delisted from 1 July 2024 | | |
| 93 | FLUCLOXACILLIN (↑ price and addition of PSS)
Inj 250 mg vial – 5% DV Jul-24 to 2026 42.60 | 10 | Flucloxin |
| | Inj 500 mg vial – 5% DV Jul-24 to 2026 45.63 | 10 | Flucloxin |

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 February 2024 (continued)

96	METHENAMINE (HEXAMINE) HIPPURATE (new listing) Tab 1 g – 5% DV Feb-23 to 2025	19.95	100	Hiprex
Note – new Pharmacode listing, 2671077. Hiprex tab 1 mg, Pharmacode 209538 to be delisted from 1 July 2024.				

MUSCULOSKELETAL SYSTEM

113	ALENDRONATE SODIUM († price and addition of PSS) Tab 70 mg – 5% DV Jul-24 to 2026	3.10	4	Fosamax
113	ALENDRONATE SODIUM WITH COLECALCIFEROL († price and addition of PSS) Tab 70 mg with colecalciferol 5,600 iu – 5% DV Jul-24 to 2026	1.99	4	Fosamax Plus

NERVOUS SYSTEM

126	MORPHINE SULPHATE († price) Oral liq 2 mg per ml	16.31	100 ml	Wockhardt
-----	---	-------	--------	-----------

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

161	NILOTINIB (amended restriction criteria – amended criteria shown only) → Cap 150 mg	4,680.00	120	Tasigna
	→ Cap 200 mg	6,532.00	120	Tasigna
Initiation Haematologist <i>Re-assessment required after 6 months</i> All of the following:				
1 Patient has a diagnosis of chronic myeloid leukaemia (CML) in blast crisis, high risk chronic accelerated phase, or in chronic phase; and				
2 Either:				
2.1 Patient has documented CML treatment failure* with a tyrosine kinase inhibitor (TKI) imatinib ; or				
2.2 Patient has experienced treatment limiting toxicity with a tyrosine kinase inhibitor (TKI) imatinib precluding further treatment with imatinib ; and				
3 Maximum nilotinib dose of 800 mg/day; and				
4 Subsidised for use as monotherapy only.				
Note: *treatment failure as defined by Leukaemia Net Guidelines.				

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 February 2024 (continued)

SENSORY ORGANS

260 POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL (new listing)

Eye drops 0.4% with propylene glycol 0.3%, 10 ml bottle

Note: Only for use in compounding an eye drop formulation

SPECIAL FOODS

273 Metabolic Products (amended restriction criteria)

Restricted

Initiation

Any of the following:

- 1 For the dietary management of ~~homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria, isovaleric acidemia, propionic acidemia, methylmalonic acidemia, tyrosinaemia or urea cycle disorders~~ **inherited metabolic disease**; or
- 2 Patient has adrenoleukodystrophy; or
- 3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

273 **Supplements for Glutaric Aciduria Type 1 Products** (amended Therapeutic Group heading and new listing)

AMINO ACID FORMULA (WITHOUT LYSINE)

- Powder 15 g protein, 3.4 g carbohydrate,
0.05 g fat per 25 g sachet 1,048.95 30 GA Express 15
- Powder 5 g protein, 5.3 g carbohydrate,
0.2 g fat per 12.5 g sachet 349.65 30 GA Explore 5

274 **Supplements for Homocystinuria Products** (amended Therapeutic Group heading and new listing)

AMINO ACID FORMULA (WITHOUT METHIONINE)

- Powder 15 g protein, 3.5 g carbohydrate,
0.55 g fat per 25 g sachet 1,048.95 30 HCU Express 15
- Powder 5 g protein, 5.3 g carbohydrate,
0.2 g fat per 12.5 g sachet 349.65 30 HCU Explore 5

274 **Supplements for MSUD and Short chain enoyl coA hydratase deficiency Maple Syrup Urine Disease Products** (amended Therapeutic Group heading and new listing)

AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE)

- Powder 15 g protein, 3.5 g carbohydrate,
0.6 g fat per 25 g sachet 1,048.95 30 MSUD Express 15
- Powder 5 g protein, 5.3 g carbohydrate,
0.2 g fat per 12.5 g sachet 349.65 30 MSUD Explore 5

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 February 2024 (continued)

275	Supplements for Phenylketonuria Products (amended Therapeutic Group heading and new listing)			
	AMINO ACID FORMULA (WITHOUT PHENYLALANINE)			
	→ Powder (Berry), 5.0 g protein, 14 g carbohydrate, 0 g fat per 20 g sachet	449.28	60	PKU Restore Powder
	→ Powder (Lemon), 20 g protein, 3.9 g carbohydrate, 0.8 g fat per 34 g sachet	883.50	30	PKU Express 20
	→ Powder (Neutral), 20 g protein, 4.8 g carbohydrate, 0.8 g fat per 34 g sachet	883.50	30	PKU Express 20
	→ Powder (Neutral), 5.0 g protein, 5.2 g carbohydrate, 0.2 g fat per 12.5 g sachet	220.88	30	PKU Explore 5
	→ Powder (Orange), 10 g protein, 9.8 g carbohydrate, 0.4 g fat per 25 g sachet	441.75	30	PKU Explore 10
	→ Powder (Orange), 20 g protein, 3.9 g carbohydrate, 0.8 g fat per 34 g sachet	883.50	30	PKU Express 20
	→ Powder (Orange), 5.0 g protein, 14 g carbohydrate, 0 g fat per 20 g sachet	449.28	60	PKU Restore Powder
	→ Powder (Raspberry), 10 g protein, 9.8 g carbohydrate, 0.4 g fat per 25 g sachet	441.75	30	PKU Explore 10
	→ Powder (Tropical), 20 g protein, 3.9 g carbohydrate, 0.8 g fat per 34 g sachet	883.50	30	PKU Express 20
	→ Powder (Neutral), 14.3 g protein, 25 g fat per 100 g, can	178.79	400 g	PKU Start
276	Supplements for Phenylketonuria Products (amended Therapeutic Group heading and new listing)			
	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE			
	→ Powder (Neutral), 10 g protein, 0.5 g carbohydrate, 0.6 g fat per 16 g sachet	449.28	30	PKU Build 10
	→ Powder (neutral), 15 g protein, 15 g carbohydrate, 4.5 g fat per 40 g sachet	673.92	30	Camino Pro Bettermilk
	→ Liquid (Coffee Mocha), 15 g protein, 3.1 g carbohydrate, 4.6 g fat 250 ml, carton.....	684.45	30	PKU Glytactin RTD 15 Lite
	→ Liquid (chocolate), 15 g protein, 22 g carbohydrate, 5.3 g fat per 250 ml, carton.....	684.45	30	PKU Glytactin RTD 15
	→ Liquid (neutral), 15 g protein, 22 g carbohydrate, 5.3 g fat per 250 ml, carton.....	684.45	30	PKU Glytactin RTD 15
	→ Liquid (vanilla), 15 g protein, 3.3 g carbohydrate, 4.6 g fat per 250 ml, carton.....	684.45	30	PKU Glytactin RTD 15 Lite

→ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 February 2024 (continued)

276	Supplements for Phenylketonuria (moved chemical to new Therapeutic Group and revoke delisting) GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE → Powder 20 g protein, 1.7 g carbohydrate per 32 g sachet.....	898.56	30	PKU Build 20 Chocolate PKU Build 20 Raspberry Lemonade PKU Build 20 Vanilla
	→ Powder 20 g protein, 6.0 g carbohydrate per 35 g sachet.....	930.00	30	PKU sphere20 Lemon
	→ Powder 20 g protein, 6.3 g carbohydrate per 35 g sachet.....	930.00	30	PKU sphere20 Chocolate PKU sphere20 Red Berry PKU sphere20 Vanilla
	→ Powder 20 g protein, 6.7 g carbohydrate per 35 g sachet.....	930.00	30	PKU sphere20 Banana
	Note—PKU Build 20 Chocolate, PKU Build 20 Raspberry Lemonade, PKU Build 20 Smooth, PKU Build 20 Vanilla, PKU sphere20 Lemon, PKU sphere20 Chocolate, PKU sphere20 Red Berry, PKU sphere20 Vanilla and PKU sphere20 Banana to be delisted from 1 March 2024			
277	Supplements for Tyrosinaemia Products (amended Therapeutic Group heading and new listing) AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) → Powder (neutral), 5 g protein, 5.3 g carbohydrate, 0.2 g fat per 12.5 g sachet	349.65	30	TYR Explore 5
	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME TYROSINE AND PHENYLALANINE → Powder (Red Berry), 20 g protein, 6.3 carbohydrate, 1.6 g fat per 35 g sachet	1,398.60	30	TYR Sphere 20
	→ Powder (Vanilla), 20 g protein, 6.0 g carbohydrate, 1.6 g fat per 35 g sachet	1,398.60	30	TYR Sphere 20
277	Supplements for Urea Cycle Disorders Products (amended Therapeutic Group heading)			
277	Supplements for Glycogen Storage Disease (new listing) HIGH AMYLOPECTIN CORN-STARCH → Powder 0 g protein, 53 g carbohydrate, 0 g fat per 60 g sachet	241.62	30	Glycosade
277	Supplements for Organic Acidaemias (moved chemicals to new Therapeutic Group heading) AMINO ACID FORMULA (WITHOUT LEUCINE) → Powder 13.1 g protein, 49.5 carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. IVA Anamix Infant
	→ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. XLEU Maxamaid
	→ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. XLEU Maxamum
	AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE) → Powder 13.1 g protein, 50.1 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can			e.g. MMA/PA Anamix Infant
	→ Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can			e.g. XMTVI Maxamaid
	→ Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can			e.g. XMTVI Maxamum

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 February 2024 (continued)

277	Supplements for Organic Acidaemias (new listing) AMINO ACID FORMULA (WITHOUT METHIONINE, THREONINE AND VALINE) → Powder 5 g protein, 5.3 g carbohydrate, 0.2 g fat per 12.5 g sachet 349.65	30	MMA/PA Explore 5
	→ Powder 15 g protein, 3.4 g carbohydrate, 0.05 g fat per 25 g sachet 1,048.95	30	MMA/PA Express 15
277	Single Dose Amino Acids (new listing) ARGININE → Powder 1.7 g protein, 1.9 g carbohydrate per 4 g sachet..... 211.45	30	Arginine2000
	CITRULLINE → Powder 0.8 g protein, 2.9 g carbohydrate per 4 g sachet..... 211.45	30	Citrulline1000
	ISOLEUCINE → Powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet..... 141.05	30	Isoleucine50
	LEUCINE → Powder 0.08 g protein, 3.7 g carbohydrate per 4 g sachet..... 141.05	30	Leucine100
	PHENYLALANINE → Powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet..... 141.05	30	Phenylalanine50
	TYROSINE → Powder 0.8 g protein, 2.9 g carbohydrate per 4 g sachet..... 211.45	30	Tyrosine1000
	VALINE → Powder 0.04 g protein, 3.8 g carbohydrate per 4 g sachet..... 141.05	30	Valine50
275	LOW-GI ENTERAL FEED 1 KCAL/ML (↑ price) → Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 500 ml bottle 4.65	500 ml	Glucerna Select
276	PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML (↑ price) → Liquid 6.75 g protein, 18.4 g carbohydrate and 5.5 g fat per 100 ml, bottle 22.39	1,000 ml	Vital
277	ENTERAL FEED 2 KCAL/ML (↑ price) → Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, bottle..... 13.64	1,000 ml	Ensure Two Cal HN RTH
279	AMINO ACID FORMULA (↑ price) → Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can 65.72	400 g	Elecare LCP (Unflavoured)
	→ Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, can 65.72	400 g	Elecare (Unflavoured) Elecare (Vanilla)

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 February 2024 (continued)

282	PAEDIATRIC ENTERAL FEED 1 KCAL/ML (↑ price) → Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bag	3.32	500 ml	Pediasure RTH
283	PAEDIATRIC ORAL FEED 1 KCAL/ML (↑ price) → Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, bottle	1.33	200 ml	Pediasure (Chocolate) Pediasure (Strawberry) Pediasure (Vanilla)
	→ Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, can	1.66	250 ml	Pediasure (Vanilla)
283	PAEDIATRIC ORAL FEED 1.5 KCAL/ML (new listing) → Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 500 ml bottle.....	8.67	500 ml	Pediasure Plus
283	LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML (delisting) → Liquid 8.1 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, bottle.....	6.08	500 ml	Nepro HP RTH
	Note – Nepro HP RTH to be delisted from 1 August 2024			
283	LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML (↑ price) → Liquid 8 g protein, 14.74 g carbohydrate, 9.77 g fat and 1.26 g fibre per 100 ml, carton.....	3.31	220 ml	Nepro HP (Strawberry) Nepro HP (Vanilla)
284	ENTERAL FEED 1.5 KCAL/ML (↑ price) → Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, can	2.17	250 ml	Ensure Plus HN
	→ Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, bag	8.68	1,000 ml	Ensure Plus HN RTH
	→ Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, bag.....	8.68	1,000 ml	Jevity HiCal RTH
285	ENTERAL FEED 1 KCAL/ML (↑ price) → Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, bottle	6.56	1,000 ml	Osmolite RTH
	→ Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, bottle.....	6.56	1,000 ml	Jevity RTH
285	ENTERAL FEED 1.2 KCAL/ML (new listing) → Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1,000 ml bag.....	7.87	1,000 ml	Jevity Plus RTH

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 February 2024 (continued)

VACCINES

296	INFLUENZA VACCINE (new listing and amended restriction criteria) → Inj 60 mcg in 0.5 ml syringe (quadrivalent vaccine)	120.00	10	Influvac Tetra (2024 formulation)
-----	--	--------	----	--------------------------------------

Restricted

Initiation – People over 65

The patient is 65 years of age or over.

~~Initiation – People of Māori or any Pacific ethnicity~~

~~People 55 to 64 years of age (inclusive) and is Māori or of any Pacific ethnicity, from 1 April 2023 to 31 December 2023.~~

~~Initiation – cardiovascular disease for patients 3 years and over~~

Any of the following:

- 1 Ischaemic heart disease; or
- 2 Congestive heart failure; or
- 3 Rheumatic heart disease; or
- 4 Congenital heart disease; or
- 5 Cerebro-vascular disease.

Note: hypertension and/or dyslipidaemia without evidence of end-organ disease is excluded from funding.

~~Initiation – chronic respiratory disease for patients 3 years and over~~

Either:

- 1 Asthma, if on a regular preventative therapy; or
- 2 Other chronic respiratory disease with impaired lung function.

Note: asthma not requiring regular preventative therapy is excluded from funding.

~~Initiation – Other conditions for patients 3 years and over~~

Either:

- 1 Any of the following:
 - 1.1 Diabetes; or
 - 1.2 chronic renal disease; or
 - 1.3 Any cancer, excluding basal and squamous skin cancers if not invasive; or
 - 1.4 Autoimmune disease; or
 - 1.5 Immune suppression or immune deficiency; or
 - 1.6 HIV; or
 - 1.7 Transplant recipient; or
 - 1.8 Neuromuscular and CNS diseases/ disorders; or
 - 1.9 Haemoglobinopathies; or
 - 1.10 Is a child on long term aspirin; or
 - 1.11 Has a cochlear implant; or
 - 1.12 Errors of metabolism at risk of major metabolic decompensation; or
 - 1.13 Pre and post splenectomy; or
 - 1.14 Down syndrome; or
 - 1.15 Is pregnant; or
 - 1.16 Is a child 4 years of age or under (inclusive) who has been hospitalised for respiratory illness or has a history of significant respiratory illness; or
- 2 Patients in a long-stay inpatient mental health care unit or who are compulsorily detained long-term in a forensic unit within a Public Hospital.

continued...

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

Price		Brand or
(ex man. Excl. GST)		Generic
\$	Per	Manufacturer

Changes to Section H Part II – effective 1 February 2024 (continued)

continued...

Initiation – Serious mental health conditions or addiction

Any of the following:

- 1 schizophrenia; or
- 2 major depressive disorder; or
- 3 bipolar disorder; or
- 4 schizoaffective disorder; or
- 5 person is currently accessing secondary or tertiary mental health and addiction services.

Index

Pharmaceuticals and brands

A			
ACITRETIN.....	7	Fosamax.....	8
ALENDRONATE SODIUM.....	8	Fosamax Plus	8
ALENDRONATE SODIUM WITH COLECALCIFEROL	8	G	
AMINO ACID FORMULA	12	GA Explore 5.....	9
AMINO ACID FORMULA (WITHOUT ISOLEUCINE, LEUCINE AND VALINE).....	9	GA Express 15.....	9
AMINO ACID FORMULA (WITHOUT ISOLEUCINE, METHIONINE, THREONINE AND VALINE).....	11	Glucerna Select.....	12
AMINO ACID FORMULA (WITHOUT LEUCINE)	11	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME PHENYLALANINE	10, 11
AMINO ACID FORMULA (WITHOUT LYSINE).....	9	GLYCOMACROPEPTIDE AND AMINO ACID CONTAINS SOME TYROSINE AND PHENYLALANINE	11
AMINO ACID FORMULA (WITHOUT METHIONINE)	9	Glycosade.....	11
AMINO ACID FORMULA (WITHOUT METHIONINE, THREONINE AND VALINE).....	12	H	
AMINO ACID FORMULA (WITHOUT PHENYLALANINE).....	10	HCU Explore 5.....	9
AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE)	11	HCU Express 15.....	9
ARGININE	12	HIGH AMYLOPECTIN CORN-STARCH	11
Arginine2000	12	Hiprex.....	8
B		I	
BETAMETHASONE DIPROPIONATE	7	INFLUENZA VACCINE	14
C		Influvac Tetra (2024 formulation)	14
Camino Pro Bettermilk.....	10	ISOLEUCINE.....	12
CITRIC ACID WITH MAGNESIUM CARBONATE HYDRATE AND SODIUM PICOSULFATE	7	Isoleucine50	12
CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE.....	7	IVA Anamix Infant.....	11
CITRULLINE	12	J	
Citrulline1000	12	Jevity HiCal RTH	13
CLARITHROMYCIN.....	7	Jevity Plus RTH.....	13
D		Jevity RTH	13
DABIGATRAN.....	7	K	
Diprosone	7	Klacid IV	7
E		L	
Elecare LCP (Unflavoured).....	12	LEUCINE.....	12
Elecare (Unflavoured).....	12	Leucine100.....	12
Elecare (Vanilla)	12	LOW ELECTROLYTE ENTERAL FEED 1.8 KCAL/ML	13
Ensure Plus HN	13	LOW ELECTROLYTE ORAL FEED 1.8 KCAL/ML ..	13
Ensure Plus HN RTH	13	LOW-GI ENTERAL FEED 1 KCAL/ML	12
Ensure Two Cal HN RTH	12	M	
ENTERAL FEED 1.2 KCAL/ML	13	MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE, SODIUM CHLORIDE AND CITRIC ACID WITH MAGNESIUM CARBONATE HYDRATE AND SODIUM PICOSULFATE.....	7
ENTERAL FEED 1.5 KCAL/ML	13	MACROGOL 3350 WITH ASCORBIC ACID, POTASSIUM CHLORIDE, SODIUM CHLORIDE AND CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE	7
ENTERAL FEED 1 KCAL/ML	13	METHENAMINE (HEXAMINE) HIPPURATE	8
ENTERAL FEED 2 KCAL/ML	12	MMA/PA Anamix Infant	11
F		MMA/PA Explore 5	12
FLUCLOXACILLIN.....	7	MMA/PA Express 15	12
Flucloxin	7		

Index

Pharmaceuticals and brands

MORPHINE SULPHATE	8	PKU Express 20	10
MSUD Explore 5	9	PKU Glytactin RTD 15	10
MSUD Express 15	9	PKU Glytactin RTD 15 Lite	10
N		PKU Restore Powder	10
Nepro HP RTH	13	PKU sphere20 Banana	11
Nepro HP (Strawberry)	13	PKU sphere20 Chocolate	11
Nepro HP (Vanilla)	13	PKU sphere20 Lemon	11
NILOTINIB	8	PKU sphere20 Red Berry	11
Novatretin	7	PKU sphere20 Vanilla	11
O		PKU Start	10
Osmolite RTH	13	POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL	9
P		Pradaxa	7
PAEDIATRIC ENTERAL FEED 1 KCAL/ML	13	Prepkit-O	7
PAEDIATRIC ORAL FEED 1.5 KCAL/ML	13	Prepkit Orange	7
PAEDIATRIC ORAL FEED 1 KCAL/ML	13	T	
Pediasure (Chocolate)	13	Tasigna	8
Pediasure Plus	13	TYR Explore 5	11
Pediasure RTH	13	TYROSINE	12
Pediasure (Strawberry)	13	Tyrosine1000	12
Pediasure (Vanilla)	13	TYR Sphere 20	11
PEPTIDE-BASED ENTERAL FEED 1.5 KCAL/ML ..	12	V	
PHENYLALANINE	12	VALINE	12
Phenylalanine50	12	Valine50	12
PicoPrep	7	Vital	12
PicoPrep Orange	7	X	
PKU Build 10	10	XLEU Maxamaid	11
PKU Build 20 Chocolate	11	XLEU Maxamum	11
PKU Build 20 Raspberry Lemonade	11	XMTVI Maxamaid	11
PKU Build 20 Vanilla	11	XMTVI Maxamum	11
PKU Explore 5	10		
PKU Explore 10	10		

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

